McKesson raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00, implying 15-17% growth at the midpoint, after first-quarter revenues rose 8% to $105.4 billion and adjusted EPS climbed 20% to $9.93. The oncology and multispecialty segment drove much of the momentum, with revenues up 33% to $14.2 billion and operating profit up 41%, or roughly 24% revenue growth excluding the Core Ventures acquisition, and management now expects 14.5-18.5% segment revenue growth for fiscal 2027. North American Pharmaceutical generated $15 billion of GLP-1 distribution revenues in the quarter, more than 14% of total revenues, up approximately 24% year over year and 13% sequentially. Offsetting those gains, the medical-surgical solutions segment posted just 4% revenue growth to $2.8 billion while operating profit fell 20% to $195 million, and management guided to only 1-6% revenue growth and flat-to-4% operating-profit growth for that unit in fiscal 2027. McKesson also flagged continued uncertainty from 340B reform and the IRA Part D framework, which is not scheduled to take effect until January 2028, while the Zacks Consensus Estimate for fiscal 2027 EPS has improved 3 cents to $44.64 over the past 30 days.
Globus Medical
Intuitive Surgical IncMcKesson CorporationRaised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 after Q1 revenue rose 8% and adjusted EPS climbed 20% to $9.93.
Veracyte Inc